<?xml version="1.0" encoding="UTF-8"?>
<p>The manufacturer of Remdesivir, Gilead Sciences, Inc., sponsored two randomized, open-label, multi-center phase 3 clinical trials (also known as SIMPLE studies) that were developed in countries with a large number of cases: (1) SIMPLE trial 1 was developed on severe COVID-19 patients in order to assess the effectiveness and the safety of a 5-day versus 10-day treatment with RDV (first dose—200 mg/day intravenously administration, followed by 100 mg/day for 4 or 9 days, respectively) in addition to standard care, and (2) SIMPLE trial 2 performed on patients with moderate COVID-19 symptomatology aiming to evaluate the effectiveness and the safety of a 5-day or 10-day treatment with RDV versus standard care—the results will be available by the end of May [
 <xref rid="B57-jcm-09-02084" ref-type="bibr">57</xref>].
</p>
